CHỈ SỐ ĐÁNH GIÁ XƠ HÓA GAN FIBROSIS-4 (FIB-4) Ở BỆNH NHÂN SUY TIM NẰM VIỆN

Abstract

Background: Cirrhosis is common in patients with heart failure (HF). The FIB-4 index used to evaluate liver fibrosis is a good prognostic marker of mortality and rehospitalization in HF patients. Objective: We observed three groups of Fibrosis-4 index: low (< 1.3), medium (1.3 - 2.67), high (> 2.67) about clinical and subclinical characteristics, groups of drugs to treat HF in hospitalized patients with chronic HF including reduced left ventricular ejection fraction (LVEF) (HFrEF), mid-range LVEF (mrEF) and preserved LVEF (pEF). Methods: 319 patients with chronic HF, 18 years of age or older, admitted to the Department of Cardiology, University of Medicine and Pharmacy Hospital, Ho Chi Minh City, were defined liver Fibrosis-4 index. Results: From January 2022 to May 2023, 319 patients met the inclusive criteria, without exclusion criteria. This study enrolled 88 HF patients with low FIB-4 index (< 1.3), 145 patients had average FIB-4 index (1.3 - 2.67) and 86 patients with high FIB-4 index (> 2.67). We recorded a statistically significant increase in the FIB-4 group > 2.67, in age, AST, NT-ProBNP values regardless of ejection fraction groups (P < 0.05). Besides, in any the ejection fraction groups, the platelet count, eGFR of FIB-4 patients > 2.67 were also significantly lower than the other 2 FIB-4 groups (P < 0.05). Conclusions: High FIB-4 correlates with an increase in age, elevation of AST, NT-proBNP and decline in platelets, eGFR in patients with HF.